Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
aducanumab
2
×
biotech
2
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
2
×
san diego blog main
san diego top stories
san francisco blog main
2
×
san francisco top stories
seattle blog main
seattle top stories
sherlock biosciences
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
acc
acquisition
activist investor
adalimumab (humira)
aduro biotech
affordable care act
alez azar
alzheimer's disease
alzheimer's failure
What
bio
drug
2
×
news
roundup
adu
approval
approved
beats
bids
biogen
biogen’s
biopharmaceutical
companies
complicated
convo
depression
dire
earlier
failures
good
group
heart
help
littered
medical
nash
need
new
people
postpartum
price
relief
remains
road
sage
strategy
talk
week
Language
Current search:
aducanumab
×
drug
×
biotech
×
" san francisco blog main "
×
" raleigh-durham top stories "
×
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More